Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.49 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | RORA | P35398 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | RORB | Q92753 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12348264 | 0.95 | OXER1 (0.53) | PRKCIOXER1S1PR1CYP2A6RORA | |
| SCHEMBL18876154 | 0.89 | PRKCI (0.52) | PRKCIOXER1S1PR1CYP2A6HSD11B1 | |
| SCHEMBL27672700 | 0.82 | PRKCI (0.45) | PRKCIOXER1CYP2A6CHRNA7FAAH | |
| SCHEMBL8738295 | 0.82 | PRKCI (0.55) | PRKCICYP2A6HSD11B1CHRNA7FAAH | |
| SCHEMBL14402803 | 0.81 | OXER1 (0.53) | OXER1S1PR1CYP2A6RORARORC | |
| SCHEMBL20562931 | 0.81 | PRKCI (0.59) | PRKCICYP2A6HSD11B1CHRNA7FAAH | |
| SCHEMBL14402849 | 0.81 | PRKCI (0.50) | PRKCICYP2A6HSD11B1CHRNA7FAAH | |
| SCHEMBL28909178 | 0.81 | PRKCI (0.50) | PRKCICYP2A6HSD11B1CHRNA7FAAH | |
| SCHEMBL30046101 | 0.81 | PRKCI (0.50) | PRKCICYP2A6HSD11B1CHRNA7FAAH | |
| SCHEMBL14161622 | 0.80 | PRKCI (0.46) | PRKCIOXER1S1PR1CYP2A6HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110709-B2 | Stabilization of hydroformylation catalysts based on phosphoramide ligands | BASF SE (DE) | 2012-02-07 | — | — | US | disclosed |
| US-20100048959-A1 | METHOD FOR THE HYDROFORMYLATION OF OLEFINS | BASF SE (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20090227801-A1 | LIGANDS FOR USE IN ASYMMETRIC HYDROFORMYLATION | BASF AKTIENGESELLSCHAFT (DE) | 2009-09-10 | — | — | US | disclosed |
| EP-1539666-B1 | METHOD FOR PRODUCING DIALDEHYDES AND/OR ETHYLENICALLY UNSATURATED MONOALDEHYDES BY HYDROFORMYLATING ETHYLENICALLY UNSATURATED COMPOUNDS | BASF SE (DE) | 2009-01-07 | — | — | EP | disclosed |
| US-20080083606-A1 | preparing aminodihalophosphines, diaminohalophosphines, triaminophosphines, phosphorous ester diamides, aminophosphines, diaminophosphines, phosphorous ester amide halides and aminophosphine halides with elimination of an acid in the presence of an auxiliary base | BASF AKTIENGESELLSCHAFT (DE) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227801-A1 | LIGANDS FOR USE IN ASYMMETRIC HYDROFORMYLATION | PFKFB3, PHPT1, PFKFB4 | PRKCI 2175/4885OXER1 1686/4885S1PR1 1799/4885 |
| US-20100048959-A1 | METHOD FOR THE HYDROFORMYLATION OF OLEFINS | DOHH, CYP4F3, DHPS | PRKCI 2785/4885OXER1 265/4885S1PR1 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.